Ovid Therapeutics Inc. Cash Flow Statement
OVID|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Ovid Therapeutics Inc. used $56M in operating cash flow and negative free cash flow of $56M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$26.4M | -$52.3M | -$54.2M | $122.8M |
| Depreciation & Amortization | $613.0K | $568.0K | $512.5K | $237.1K |
| Operating Cash Flow | -$56.0M | -$45.8M | -$55.2M | $118.6M |
| Capital Expenditures | $71.0K | $40.0K | $1.2M | $184.0K |
| Free Cash Flow | -$56.0M | -$45.8M | -$56.5M | $118.4M |
| FCF Margin | -9898.8% | -11689.0% | -3756.6% | 56.8% |